Urothelial Cancer Clinical Trial
Official title:
A Multicentre Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients With Advanced Urothelial Cancer Progressing on or After a Platinum Containing Regimen.
The purpose of this study is to compare the effects on urothelial cancer of nab-paclitaxel compared to paclitaxel to treat this disease. This research is being done because currently there is no effective treatment for urothelial cancer that has progressed after prior chemotherapy.
Nab-paclitaxel is a formulation of the chemotherapeutic drug paclitaxel that is combined with a human protein called albumin. In Canada, nab-paclitaxel is currently approved for the treatment of metastatic breast cancer. This drug has been tested in other cancers and has shown promising activity in lung cancer, melanoma and pancreatic cancer. Information from research studies suggests that nab-paclitaxel may be a useful treatment for urothelial cancer. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
| Terminated |
NCT01663285 -
Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
|
Phase 2 | |
| Recruiting |
NCT00872495 -
Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
|
||
| Terminated |
NCT04629339 -
Study of INCB086550 in Select Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT04114136 -
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
|
Phase 2 | |
| Completed |
NCT03219333 -
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
|
Phase 2 | |
| Terminated |
NCT04501094 -
A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma
|
Phase 2 | |
| Recruiting |
NCT04923178 -
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
|
||
| Completed |
NCT02256436 -
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
|
Phase 3 | |
| Terminated |
NCT00995488 -
Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer
|
Phase 2 | |
| Completed |
NCT01206426 -
Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer
|
||
| Active, not recruiting |
NCT03425201 -
Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03288545 -
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03983954 -
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04180371 -
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02891161 -
Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT01700010 -
Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02516241 -
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT04152018 -
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
|
Phase 1 |